Summary
This prediction ended on 19.03.18 with a price of €14.55. During the runtime of the prediction for GSK plc the price only changed by 0.20%. melinda has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| GSK plc | -6.044% | -6.044% | 40.313% | 39.674% |
| iShares Core DAX® | -1.741% | 5.979% | 8.977% | 49.858% |
| iShares Nasdaq 100 | 2.815% | 11.827% | 38.406% | 100.330% |
| iShares Nikkei 225® | -0.109% | 11.692% | 46.680% | 65.355% |
| iShares S&P 500 | 0.966% | 7.616% | 28.141% | 68.657% |
According to melinda what are the pros and cons of GSK plc for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread GlaxoSmithKline plc diskutieren
Pharmazeutische SecteurProduits Agenda 25/04 Ergebnisse Veröffentlichung
GSK stellt fest , dass ViiV Healthcare verkündet positive Daten Dolutegravir
5. März (Reuters) - Glaxosmithkline Plc :: GLAXOSMITHKLINE PLC - ViiV Healthcare KÜNDIGT NEUE DATEN ZUR BEHANDLUNG VON MENSCHEN POSITIVE Dolutegravir mit HIV-Infizierte mit TUBERCULOSIS.GLAXOSMITHKLINE CO PLC - Dolutegravir WANN 50mg zweimal täglich zu MIT NUCLEOSID DOUBLE REVERSE.